A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes-Reference-Cited by-同舟云学术

A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes

Published:2016-06-13 Issue:7 Volume:22 Page:727-734
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Fang Jing,Liu Xiaona,Bolanos Lyndsey,Barker Brenden,Rigolino Carmela,Cortelezzi Agostino,Oliva Esther N,Cuzzola Maria,Grimes H Leighton^ORCID,Fontanillo Celia,Komurov Kakajan,MacBeth Kyle,Starczynowski Daniel T

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/nm.4127.pdf

Reference36 articles.

1. Pan, B. & Lentzsch, S. The application and biology of immunomodulatory drugs (IMiDs) in cancer. Pharmacol. Ther. 136, 56–68 (2012).

2. List, A. et al. Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N. Engl. J. Med. 355, 1456–1465 (2006).

3. Giagounidis, A.A. Lenalidomide for del(5q) and non-del(5q) myelodysplastic syndromes. Semin. Hematol. 49, 312–322 (2012).

4. Wei, S. et al. Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene 32, 1110–1120 (2013).

5. McDaniel, J.M., Pinilla-Ibarz, J. & Epling-Burnette, P.K. Molecular action of lenalidomide in lymphocytes and hematologic malignancies. Adv. Hematol. 2012, 513702 (2012).

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Ubiquitin-Conjugating Enzyme E2 O (UBE2O) and Its Therapeutic Potential in Human Leukemias and Solid Tumors;Cancers;2024-09-03

2. The Roles of Proton-Sensing G-Protein-Coupled Receptors in Inflammation and Cancer;Genes;2024-09-01

3. LILRB4 regulates multiple myeloma development through STAT3-PFKFB1 pathway;Cell Death & Disease;2024-07-18

4. The evolution of preclinical models for myelodysplastic neoplasms;Leukemia;2024-02-23

5. Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications;European Journal of Haematology;2024-01-31